Microvesicles derived from mesenchymal stem cells inhibit acute respiratory distress syndrome-related pulmonary fibrosis in mouse partly through hepatocyte growth factor

Figure 6 Effects of mesenchymal stromal cell-derived microvesicles on pulmonary vascular endothelial permeability and related proteins in acute respiratory distress syndrome pulmonary fibrosis mouse models. A: Lung wet/dry weight ratios for each group; B: Evans blue detection of vascular endothelial permeability in each group; C: Hydroxyproline levels in each group; D: Expression of inflammatory factors in each group detected by ELISA. ^aP < 0.05, vs the control group; ^bP < 0.05, vs the pulmonary fibrosis group; ^cP < 0.05, vs the mesenchymal stromal cell-derived microvesicles (MSC-MVs) group (n = 6). Control, acute respiratory distress syndrome (ARDS), pulmonary fibrosis, MSC, MSC-MVs and low hepatocyte growth factor (HGF)-MSC-MVs represent the control group, ARDS group, pulmonary fibrosis group, MSC group, MSC-MVs group and low HGF-MSC-MVs group, respectively. IL: Interleukin; PIIIP: Type III procollagen N-terminal aminopeptide; TGF-β1: Transforming growth factor-β1.